Skip to main content

ADVERTISEMENT

Devices

01/01/2020

CLD talks with Samin K. Sharma, MD, FACC, FSCAI, Director, Clinical and Interventional Cardiology; President, Mount Sinai Heart Network; Dean of International Clinical Affiliations; Anandi Lal Sharma Professor of Medicine, The Mount Sinai Hospital New York, New York.

CLD talks with Samin K. Sharma, MD, F...
Our policy at Mount Sinai Hospital is that for every percutaneous coronary intervention (PCI), we open the Runthrough NS. It is at 100% use in our interventions.
Our policy at Mount Sinai Hospital is that for every percutaneous coronary intervention (PCI), we open the Runthrough NS. It is at 100% use in our interventions.
Our policy at Mount Sinai...
01/01/2020
Cath Lab Digest
Two-Year Results of IMPERIAL: First-Ever Randomized Study of Eluvia and Zilver PTX in  Femoropopliteal Artery Lesions
Calcium Corner
01/01/2020

An interview with IMPERIAL trial co-principal investigator William A. Gray, MD, FACC, FSCAI, System Chief, Division of Cardiovascular Disease; President, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania.

An interview with IMPERIAL trial co-p...
The Eluvia stent utilizes a drug-polymer combination that provides a sustained release of paclitaxel over one year.
The Eluvia stent utilizes a drug-polymer combination that provides a sustained release of paclitaxel over one year.
The Eluvia stent utilizes a...
01/01/2020
Cath Lab Digest
11/05/2019

An interview with Frank J. Veith, MD, Professor of Surgery, New York University-Langone Medical Center and The Cleveland Clinic Lerner College of Medicine; The William J. von Liebig Chair in Vascular Surgery; Cleveland, Ohio and New York, New York.

Dr. Veith is Founder and Chairman of VEITHsymposium, now in its 46th year.

An interview with Frank J. Veith, MD,...
Industry has been appropriately aggressive in producing paclitaxel-coated devices, which clearly have a benefit in preventing restenosis and the requirement for reintervention. Thus, paclitaxel deserves the continued attention it is getting.
Industry has been appropriately aggressive in producing paclitaxel-coated devices, which clearly have a benefit in preventing restenosis and the requirement for reintervention. Thus, paclitaxel deserves the continued attention it is getting.
Industry has been appropriately...
11/05/2019
Cath Lab Digest
03/09/2016

Jo Ann LeQuang

 

Jo Ann LeQuang  
Cardiovascular implantable electronic devices are known as being on the forefront of telemedicine, and current devices now offer some form of remote monitoring. In the early days, transtelephonic monitoring was offered; today, remote...
Cardiovascular implantable electronic devices are known as being on the forefront of telemedicine, and current devices now offer some form of remote monitoring. In the early days, transtelephonic monitoring was offered; today, remote...
Cardiovascular implantable...
03/09/2016
EP Lab Digest